Philadelphia Trust Co. bought a new position in shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) in the 4th quarter, HoldingsChannel.com reports. The fund bought 13,644 shares of the company’s stock, valued at approximately $655,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new position in Sigilon Therapeutics during the fourth quarter worth about $53,403,000. State of Wisconsin Investment Board acquired a new position in Sigilon Therapeutics during the fourth quarter worth about $24,477,000. Victory Capital Management Inc. acquired a new position in Sigilon Therapeutics during the fourth quarter worth about $3,266,000. Finally, SG Americas Securities LLC acquired a new position in Sigilon Therapeutics during the fourth quarter worth about $375,000.

In related news, major shareholder Lilly & Co Eli bought 300,000 shares of Sigilon Therapeutics stock in a transaction that occurred on Tuesday, December 8th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $5,400,000.00. Following the completion of the acquisition, the insider now directly owns 2,444,443 shares of the company’s stock, valued at approximately $43,999,974. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

SGTX has been the subject of several research analyst reports. Barclays initiated coverage on Sigilon Therapeutics in a research note on Tuesday, December 29th. They set an “overweight” rating and a $48.00 target price for the company. Morgan Stanley initiated coverage on Sigilon Therapeutics in a report on Tuesday, December 29th. They set an “equal weight” rating and a $45.00 price target on the stock. Jefferies Financial Group initiated coverage on Sigilon Therapeutics in a report on Tuesday, December 29th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Canaccord Genuity initiated coverage on Sigilon Therapeutics in a report on Friday, January 8th. They set a “buy” rating and a $62.00 price target on the stock.

NASDAQ:SGTX opened at $35.88 on Tuesday. The business’s 50-day moving average price is $35.03. Sigilon Therapeutics, Inc. has a 1-year low of $22.00 and a 1-year high of $54.32.

Sigilon Therapeutics Company Profile

Sigilon Therapeutics, Inc, a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes.

See Also: How does a security become overbought?

Want to see what other hedge funds are holding SGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sigilon Therapeutics, Inc. (NASDAQ:SGTX).

Institutional Ownership by Quarter for Sigilon Therapeutics (NASDAQ:SGTX)

Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.